Sunovion Pharmaceuticals Inc.

Pgi Drug Discovery LLC

Sumitomo Pharma America, Inc.

Linghong Xie

Philip Glyn Jones

Taleen G Hanania

Michele L R Heffernan

Kerry Leigh Spear

John Emmerson Campbell

Michael Charles Hewitt

Noel Aaron Powell

Carrie A Bowen

Vadim Alexandrov

Douglas F Burdi

Lee W Herman

Scott C Malcolm

Robert Lew

Laurence Melnick

Phillip G Jones

Philip Xinhe Jones

Michele LR Heffernan

Scott Malcolm

Disclosed are compounds of formula (I): and pharmaceutical compositions containing such compounds. Methods of treating neurological or psychiatric disease and disorders in a subject in need are also disclosed.

Compounds and compositions and uses thereof

Compounds of Formula I are described as are pharmaceutical compositions containing such compounds. Methods of treating neurological or psychiatric diseases and disorders in a subject in need are also disclosed.

Heteroaryl-isochroman compounds and uses thereof

Disclosed are compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein A, R, R, R, R, R, R, w and n1 are defined and described herein; compositions thereof; and methods of use thereof. These compounds are useful for treating a variety of neurological and psychiatric disorders, such as those described herein.

1-heterocyclyl isochromanyl compounds and analogs for treating CNS disorders

Compounds and uses thereof

Provided herein are cyclic nucleotide phosphodiesterase inhibitors, and pharmaceutical compositions thereof, useful for the treatment of, for example, central nervous system and metabolic diseases and disorder.

Substituted quinoxalines as PDE-10 inhibitors

Provided herein are heteroaryl compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. In one embodiment, the compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, such as CNS disorders and neurological disorders, including, but not limited to, e.g., psychosis, schizophrenia, depression, movement disorders, and Parkinson's disease.

D2 receptor modulators and methods of use thereof in the treatment of diseases and disorders

Provided herein are Cyclic Nucleotide Phosphodiesterase inhibitors, and pharmaceutical compositions thereof, useful for the treatment of, for example, central nervous system and metabolic diseases and disorder.

Substituted quinolines as PDE-10 inhibitors

Provided herein are compounds and methods of synthesis thereof. The compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, such as pain, neurological disorders, psychiatric disorders, and neuromuscular disorders. Compounds provided herein modulate the activity of opioid receptor (e.g., &#x3bc;-opioid receptor) in the central nervous system or the periphery. Pharmaceutical formulations containing the compounds and their methods of use are also provided herein.

Modulators of opioid receptors and methods of use thereof

Provided herein are compounds of formula A-L-B, and pharmaceutically acceptable salts and stereoisomers thereof, wherein A is Rand Rtogether with the carbon atoms to which they are attached form a 1,2-phenylene ring optionally substituted with one or more R; L is &#x2014;C(R)&#x2014;C(R)&#x2014;; B is a heteroaromatic group defined herein; and -A-A- , A, Rand Rare defined herein. Also disclosed are methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. In one embodiment, the compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, such as CNS disorders and metabolic disorders, including, but not limited to, e.g., neurological disorders, psychosis, schizophrenia, obesity, and diabetes.

Growing community of inventors

Southborough, MA, United States of America

Linghong Xie